NEW ZEALAND

Leave no stone
unturned in your
fight against cancer

Discover how FoundationOne Genomic Profiling can inform your unique cancer treatment plan.




Cancer treatment has evolved to become as unique as your cancer. Now we have medicines that target unique genomic alterations driving your cancer - so we need to find out which targeted treatment is right for you.


Comprehensive Genomic Profiling allows us to look for all types of known genomic alterations* across all of the cancer-related genes in a single sample of tumor tissue.

Find out how FoundationOne may be able to help you.

Download the fact sheet

*All types of genomic alterations: Base substitutions, copy number alterations, rearrangements, insertions and deletions, as well as tumour mutational burden (TMB) and microsatellite instability (MSI) status.

DOWNLOAD NOW

Cancer explained in 3 minutes.

Learn more about cancer and available treatment options.

How can FoundationOne Comprehensive Genomic Profiling help you?


FoundationOne may help to identify whether you could potentially benefit from targeted treatment.

Since there are hundreds of cancer genes, and many possible alterations in each gene, the type, number and combination of genomic alterations make each person’s cancer unique.

Comprehensive Genomic Profiling can search for all genomic alterations that are known to drive cancer, some of which may be promoting your tumour’s growth.

Your profiling results may help your doctor identify whether a targeted treatment option is available for your tumour’s unique genomic profile, and which treatment approach could yield the best outcome for you.

DOWNLOAD NOW

The process involved for FoundationOne Genomic Profiling

If you and your doctor decide that FoundationOne® or FoundationOne®Heme is right for you, your doctor will order the appropriate profile, and send a sample of your tumor to be analysed.

STEPS

Your doctor orders the profile.

The laboratory receives your tumor sample.

DNA is extracted from your tumor sample.

Unique genomic code of the tumor is identified.

A team of genomic experts analyses your unique data and matches your individual genomic alterations to potential targeted therapies or clinical trials.

It typically takes 14 days from the time your tissue sample is received in Boston, USA for Foundation Medicine Inc. to analyse and prepare your customised FoundationOne profile (approximately 21 days for your FoundationOneHeme profile). Also allow up to 7 days for the local laboratory to source and prepare your sample for shipment. Your doctor will receive a detailed report containing information about your tumour’s genomic makeup and potential options for you and your doctor to consider.

Find out how FoundationOne may be able to help you.

Download the fact sheet

DOWNLOAD NOW

Discuss FoundationOne with your Doctor

Speak to your Oncologist about FoundationOne and how it may be able to help you. Alternatively contact one of the private treatment providers below to discuss your options.

Private Treatment Providers

AUCKLAND & NORTHLAND


Harbour Cancer Centre


232 Wairau Road, Glenfield, Auckland www.harbourcancer.co.nz


Canopy Cancer Care


3 Fred Thomas Drive, Takapuna, Auckland www.canopycancercare.co.nz


Canopy Cancer Care

 

98 Mountain Rd, Epsom, Auckland www.canopycancercare.co.nz


Auckland Oncology

 

125 Remuera Road, Remuera, Auckland www.aucklandoncology.co.nz


WELLINGTON


Bowen Cancer Centre


Level B3, Bowen Specialist Medical Centre 

94 Churchill Drive, Crofton Downs, Wellington 6035 www.bowen.co.nz



WAIKATO


Braemar Cancer Care 


Braemar Hospital, 24 Ohaupo Road, 

Hamilton Lake, Hamilton 3204 www.braemarhospital.co.nz


BAY OF PLENTY


Canopy Cancer Care


850 Cameron Rd, Tauranga www.canopycancercare.co.nz


SOUTH ISLAND


St Georges Cancer Care Centre

131 Leinster Road, Strowan, Christchurch 8014
www.stgeorgescancercarecentre.org.nz

About Foundation Medicine

Foundation Medicine is a world-leading molecular insights company, connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands.


In New Zealand, Roche’s pharmaceutical division is the licensed distributor of FoundationOne (for patients with solid tumours) and FoundationOneHeme (for patients with haematological cancers or sarcomas), offering Comprehensive Genomic Profiling services and decision support tools that may inform cancer treatment decisions.